Exicure Secures $1.3 Million in Funding for Breakthrough Nucleic Acid Therapies Targeting Neurological Disorders and Hair Loss

Exicure, Inc., an innovative early-stage biotechnology company located in Chicago, IL, has successfully raised $1,300,000 to propel its groundbreaking work in nucleic acid therapies aimed at addressing neurological disorders and hair loss. With a dedicated team rich in expertise across nucleic acid chemistry, drug development, and neuroscience, Exicure is committed to transforming the landscape of therapeutic options for patients suffering from debilitating conditions. The funding will primarily be used to advance Exicure's lead program, a non-opioid pain analgesic targeting the genetically validated SCN9A (Nav1.7), which promises to offer a new avenue for pain relief without the risks associated with opioid medications. In addition, these funds will support the exploration of several promising candidates in addressing CNS conditions, including Huntington’s disease, Angelman syndrome, and Batten disease, which present high unmet medical needs. Exicure conducts its pioneering discovery and development efforts in-house at its state-of-the-art 30,000 sq. ft. facility, featuring advanced capabilities for high throughput nucleic acid synthesis and screening. The company’s proprietary platform is designed for high potency and prolonged efficacy, demonstrated through rigorous in vitro and in vivo validation. As Exicure embarks on this critical phase of growth, it aims not only to improve the lives of patients but also to establish itself as a frontrunner in the biotechnology sector by leveraging its unique approach to oligonucleotide chemistry and comprehensive model validation. This funding round marks an exciting step forward in the company’s mission to reshape the future of therapeutic options in neurology and beyond.